Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinobufacini for Malignant Ascites in Digestive Cancer
NCT02530398Phase 1Unknown
- Sponsor
- Beijing University of Chinese Medicine East Hospital
- Start
- Jul 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cinobufacini in gastrointestinal cancer and malignant ascites, sponsored by Beijing University of Chinese Medicine East Hospital. Primary endpoints: Adverse Events at 14 days and Vital Signs at 14 days. Status: unknown.
02
Drugs
cinobufacini
03
Conditions
gastrointestinal cancermalignant ascites
Beyond the preview
Go deeper on NCT02530398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530398.